RxDoctor Payments Data

Bridget Loehn, MD

Otolaryngology · Lake Charles, LANPI 1083875850

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,676 of the $3,976 with a category attached, or 67.3%. 19 manufacturers reported payments, led by Neurent Medical Limited at 30.0% of the total. 2025 is the largest year on record at $1,563, 9.2 times the $170 reported in 2019.

$3,976in general payments, 2019–2025

Across 125 payments — averaging $31.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurent Medical Limited$1K
  • Sanofi$865
  • Optinose US, Inc.$591
  • Acclarent, Inc$411
  • Regeneron Healthcare Solutions, Inc.$207
  • Medtronic$153
  • plus $558 from 13 others

What the payments were for

  • Travel & lodging$1,19130%
  • Food & beverage$2,67667%
  • Education$1093%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,976 in reported general payments places this provider in the 80th percentile of 218 otolaryngology providers in Louisiana.

See all otolaryngology providers in Louisiana

Medicare billing

Part B allowed, 2024
$297,423
Medicare patients
657
Services billed
8,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Epinephrine46$9,854
Montelukast Sodium530$3,797
Azelastine Hcl137$3,163
Levocetirizine Dihydrochloride182$2,734
Ipratropium Bromide84$2,150
Fluticasone Propionate134$1,699
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth11$1,432
Ofloxacin23$645
Prednisolone Acetate11$457
Pantoprazole Sodium82$389
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$375
Mometasone Furoate23$244
Nystatin15$241
Cefdinir14$150
Mupirocin27$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$37$9,85446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 218 otolaryngology providers in Louisiana.

Other otolaryngology in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →